Inpatient Migraine Cocktail Regimen
For adults with severe refractory migraine requiring inpatient treatment, administer IV prochlorperazine (10 mg) plus IV ketorolac (30 mg) as the first-line cocktail, with IV metoclopramide (10 mg) as an alternative dopamine antagonist if prochlorperazine is unavailable. 1
Core Components of the Inpatient Cocktail
The most recent and highest-quality evidence from the 2025 American Headache Society emergency department guideline provides the strongest foundation for inpatient regimens 1:
Primary Regimen (Level A - Must Offer)
- IV Prochlorperazine 10 mg - This is the only dopamine antagonist with Level A evidence (must offer) based on multiple class I studies showing it is highly likely to be effective 1
- IV Ketorolac 15-30 mg - Level B evidence (should offer) as an NSAID component, with rapid onset and 6-hour duration 2, 1
Alternative Dopamine Antagonist
- IV Metoclopramide 10 mg - Level B evidence (should offer) when prochlorperazine is contraindicated or unavailable 1
- Note: While metoclopramide is commonly used for nausea, it also has direct analgesic properties for migraine 2
Adjunctive Antiemetic Therapy
Always treat nausea proactively - antiemetics should not be restricted to patients actively vomiting, as nausea itself is one of the most disabling migraine symptoms 3
Second-Line and Rescue Options
For Refractory Cases
If the initial cocktail fails after 1-2 hours:
- IV Dexamethasone 10-24 mg - Level C (may offer) to prevent headache recurrence and treat status migrainosus 1, 4
- IV Valproate 500-1000 mg - Level C (may offer) for refractory cases 1
Migraine-Specific Agents
- Subcutaneous Sumatriptan 6 mg - Level B (should offer) with highly likely effectiveness 1
- IV Dihydroergotamine (DHE) 0.5-1 mg every 8 hours - Effective for breaking severe migraine cycles, particularly in status migrainosus 5, 6, 4
- Requires cardiac screening and contraindicated in pregnancy, cardiovascular disease, and uncontrolled hypertension
- Typically given as multi-day protocol (up to 7 days) for transformed/refractory migraine 6
- Pre-treat with antiemetic 30 minutes before DHE administration
What NOT to Use
IV Hydromorphone must NOT be offered (Level A - must not offer) based on class I evidence showing it is likely ineffective 1. This represents a critical departure from common practice:
- Opioids (meperidine, morphine, hydromorphone) lead to medication overuse headache, dependency, and eventual loss of efficacy 2
- Reserve opioids only for situations where sedation is acceptable and abuse risk has been thoroughly addressed 3
IV Paracetamol (acetaminophen) may not be offered (Level C - should not offer) as it is likely ineffective when given alone 1
Procedural Options
Greater Occipital Nerve Block (GONB) - Level A (must offer) based on multiple class I studies showing high likelihood of effectiveness 1. This can be performed at bedside and is:
- Easily learned by primary care physicians
- Less resource-intensive than IV treatments
- Has balanced risk-benefit profile with minimal adverse events
Supraorbital Nerve Block (SONB) - Level B (should offer) as an alternative nerve block approach 1
Clinical Algorithm for Inpatient Management
Step 1: Initial Assessment (First 30 minutes)
- Confirm migraine diagnosis using ICHD-3 criteria
- Screen for contraindications to dopamine antagonists (QT prolongation, Parkinson's disease, neuroleptic malignant syndrome history)
- Assess for cardiovascular risk factors if considering DHE or triptans
- Check for medication overuse (opioids, barbiturates, ergots) requiring detoxification 7
Step 2: First-Line Treatment (Hour 0)
Administer simultaneously:
- IV Prochlorperazine 10 mg over 15-30 minutes (slow push to minimize akathisia)
- IV Ketorolac 30 mg (15 mg if elderly or renal impairment)
- IV fluids (normal saline 500-1000 mL bolus for hydration)
Step 3: Reassessment (Hour 1-2)
If pain persists at moderate-severe level:
- Add IV Dexamethasone 10-24 mg (single dose)
- Consider GONB if available and patient consents
- If still refractory, consider subcutaneous sumatriptan 6 mg
Step 4: Refractory Management (Hour 2-4)
For continued severe pain despite above measures:
- Initiate IV DHE protocol 0.5-1 mg every 8 hours
- Pre-treat with antiemetic 30 minutes before each DHE dose
- Plan for multi-day admission (typically 3-7 days) 6
- Consider IV valproate 500-1000 mg as alternative
Step 5: Medication Overuse Management
If patient has been overusing acute medications (>10 days/month for triptans, >15 days/month for analgesics):
- Initiate monitored detoxification protocol
- Bridge with scheduled antiemetics and non-overused medications
- Start preventive therapy during admission 7
Critical Pitfalls to Avoid
Do not use opioids as first-line therapy - This perpetuates the cycle of refractory migraine and medication overuse 1
Do not give acetaminophen alone - It has no evidence for efficacy in migraine when used as monotherapy 3
Do not skip antiemetic pretreatment - Nausea is a primary disabling symptom requiring direct treatment, not just a side effect to manage 3
Do not use non-oral routes only for vomiting patients - Patients with early nausea benefit from parenteral administration even without vomiting 3
Do not combine DHE with triptans - Risk of prolonged vasospasm; maintain 24-hour separation 5
Divergence in Evidence
The provided guidelines show evolution over time. The 2002 guidelines 3, 2 emphasized NSAIDs and triptans with less specific inpatient guidance, while the 2025 AHS guideline 1 provides the most rigorous evidence with Level A recommendations specifically for parenteral therapy. The 2024 VA/DoD guideline 8 adds nuance about aspirin-acetaminophen-caffeine combinations but focuses on outpatient management.
The key clinical takeaway: Prochlorperazine + ketorolac represents the evidence-based foundation, with DHE protocols reserved for truly refractory cases requiring multi-day admission 1, 5, 6.